Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Anushi Bulumulle"'
Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC
Autor:
Rohini Sharma, Anjana Pillai, Thomas Urban Marron, Petros Fessas, Anwaar Saeed, Tomi Jun, Sirish Dharmapuri, David Szafron, Abdul Rafeh Naqash, Anuhya Gampa, Yinghong Wang, Uqba Khan, Mahvish Muzaffar, Chieh‐Ju Lee, Pei‐Chang Lee, Anushi Bulumulle, Sonal Paul, Dominic Bettinger, Hannah Hildebrand, Mohammed Yehia, Tiziana Pressiani, Ahmed Kaseb, Yi‐Hsiang Huang, Celina Ang, Masatoshi Kudo, Naoshi Nishida, Nicola Personeni, Lorenza Rimassa, David James Pinato
Publikováno v:
Hepatology Communications, Vol 6, Iss 7, Pp 1776-1785 (2022)
Abstract The availability of immune checkpoint inhibitors (ICIs) for the management of advanced hepatocellular cancer (HCC) has changed the treatment paradigm. There are emerging questions regarding the efficacy of subsequent anticancer therapies. Th
Externí odkaz:
https://doaj.org/article/e44c4fda0f48434e9cdc4675c1f8ec5f
Autor:
Petros Fessas, Muntaha Naeem, Matthias Pinter, Thomas U. Marron, David Szafron, Lorenz Balcar, Anwaar Saeed, Tomi Jun, Sirish Dharmapuri, Anuhya Gampa, Yinghong Wang, Uqba Khan, Mahvish Muzaffar, Musharraf Navaid, Pei-Chang Lee, Anushi Bulumulle, Bo Yu, Sonal Paul, Neil Nimkar, Dominik Bettinger, Hannah Hildebrand, Yehia I. Abugabal, Tiziana Pressiani, Nicola Personeni, Naoshi Nishida, Masatoshi Kudo, Ahmed Kaseb, Yi-Hsiang Huang, Celina Ang, Anjana Pillai, Lorenza Rimassa, Abdul Rafeh Naqash, Elad Sharon, Alessio Cortellini, David J. Pinato
Publikováno v:
Liver Cancer, Vol 10, Iss 6, Pp 583-592 (2021)
Background and Rationale: Immune checkpoint inhibitor (ICI) therapy is an expanding therapeutic option for hepatocellular carcinoma (HCC). Antibiotics (ATB) taken prior to or early during ICI therapy can impact immunotherapy efficacy across indicatio
Externí odkaz:
https://doaj.org/article/5b2616ec247c4eb78946d132559d4210
Autor:
Dominik Bettinger, David Szafron, Mahvish Muzaffar, Uqba Khan, Yi-Hsiang Huang, Ahmed Kaseb, Anwaar Saeed, Tomi Jun, Sirish Dharmapuri, Musharraf Navaid, ChiehJu Lee, Anushi Bulumulle, Sonal Paul, Petros Fessas, Neil Nimkar, Hannah Hildebrand, Tiziana Pressiani, Yehia I Abugabal, Nicola Personeni, Jingky Lozano-Kuehne, Celina Ang
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
The impact of corticosteroid therapy (CT) on efficacy of immune checkpoint inhibitors (ICI) is undefined in hepatocellular carcinoma (HCC). We evaluated whether CT administered at baseline (bCT) or concurrently with ICI (cCT) influences overall (OS),
Externí odkaz:
https://doaj.org/article/fd5dfa2eba3b4f96a6696a68a05a1a49
Autor:
David J. Pinato, Takahiro Kaneko, Anwaar Saeed, Tiziana Pressiani, Ahmed Kaseb, Yinghong Wang, David Szafron, Tomi Jun, Sirish Dharmapuri, Abdul Rafeh Naqash, Mahvish Muzaffar, Musharraf Navaid, Chieh-Ju Lee, Anushi Bulumulle, Bo Yu, Sonal Paul, Neil Nimkar, Dominik Bettinger, Hannah Hildebrand, Yehia I. Abugabal, Celina Ang, Thomas U. Marron, Uqba Khan, Nicola Personeni, Lorenza Rimassa, Yi-Hsiang Huang
Publikováno v:
Cancers, Vol 12, Iss 7, p 1862 (2020)
Immune checkpoint inhibitors (ICI) have shown positive results in patients with hepatocellular carcinoma (HCC). As liver function contributes to prognosis, its precise assessment is necessary for the safe prescribing and clinical development of ICI i
Externí odkaz:
https://doaj.org/article/6fa553ec855f4558a15583ff5163f81e
Autor:
Shravanti Macherla, Shachar Laks, Abdul Rafeh Naqash, Anushi Bulumulle, Emmanuel Zervos, Mahvish Muzaffar
Publikováno v:
International Journal of Molecular Sciences, Vol 19, Iss 11, p 3505 (2018)
Immune checkpoint blockade (ICB) with programmed cell death protein-1(PD-1)/programmed death ligand -1(PD-L1) antibodies has revolutionized the management of several cancers, especially non-small cell lung cancer, melanoma, urothelial, and renal canc
Externí odkaz:
https://doaj.org/article/44932219ac04440c8b2e8de4dce0f46f
Autor:
Hannah Hildebrand, Bo Yu, Sirish Dharmapuri, Neil Nimkar, Lorenz Balcar, Lorenza Rimassa, Pei-Chang Lee, Yehia I. Abugabal, Celina Ang, Tiziana Pressiani, David Szafron, Ahmed Kaseb, David J. Pinato, Anushi Bulumulle, Yinghong Wang, Uqba Khan, Sonal Paul, Naoshi Nishida, Mahvish Muzaffar, Muntaha Naeem, Anwaar Saeed, Yi Hsiang Huang, Thomas U. Marron, Tomi Jun, Matthias Pinter, Petros Fessas, Elad Sharon, Nicola Personeni, Musharraf Navaid, Dominik Bettinger, Anjana Pillai, Abdul Rafeh Naqash, Alessio Cortellini, Masatoshi Kudo, Anuhya Gampa
Publikováno v:
Liver Cancer, Vol 10, Iss 6, Pp 583-592 (2021)
Liver Cancer
Liver cancer, 10(6):583-592
Liver Cancer
Liver cancer, 10(6):583-592
Background and Rationale: Immune checkpoint inhibitor (ICI) therapy is an expanding therapeutic option for hepatocellular carcinoma (HCC). Antibiotics (ATB) taken prior to or early during ICI therapy can impact immunotherapy efficacy across indicatio
Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC
Autor:
Rohini Sharma, Anjana Pillai, Thomas Urban Marron, Petros Fessas, Anwaar Saeed, Tomi Jun, Sirish Dharmapuri, David Szafron, Abdul Rafeh Naqash, Anuhya Gampa, Yinghong Wang, Uqba Khan, Mahvish Muzaffar, Chieh‐Ju Lee, Pei‐Chang Lee, Anushi Bulumulle, Sonal Paul, Dominic Bettinger, Hannah Hildebrand, Mohammed Yehia, Tiziana Pressiani, Ahmed Kaseb, Yi‐Hsiang Huang, Celina Ang, Masatoshi Kudo, Naoshi Nishida, Nicola Personeni, Lorenza Rimassa, David James Pinato
Publikováno v:
Hepatology communications. 6(7)
The availability of immune checkpoint inhibitors (ICIs) for the management of advanced hepatocellular cancer (HCC) has changed the treatment paradigm. There are emerging questions regarding the efficacy of subsequent anticancer therapies. The primary
Autor:
Kirsten B. Goldberg, Thomas U. Marron, Yutao Gong, Chieh J. Lee, Celina Ang, Pallavi S. Mishra-Kalyani, Tiziana Pressiani, Thoetchai Peeraphatdit, Lola Fashoyin-Aje, Anushi Bulumulle, Elad Sharon, Mahvish Muzaffar, Alessio Cortellini, Pei Chang Lee, Ahmed Kaseb, David J. Pinato, Steven Lemery, Uqba Khan, Anwaar Saeed, Sonal Paul, Yinghong Wang, Yehia I. Abugabal, Bo Yu, Tomi Jun, Sirish Dharmapuri, Nicola Personeni, Lorenza Rimassa, Antonio D'Alessio, Guo Wei, Marc R. Theoret, Musharraf Navaid, Anuhya Gampa, Richard Pazdur, Hannah Hildebrand, Abdul Rafeh Naqash, Neil Nimkar, Yi Hsiang Huang, David Szafron, Julie A. Schneider, Lorraine Pelosof, Dominik Bettinger, Anjana Pillai
Publikováno v:
European journal of cancer (Oxford, England : 1990). 157
Purpose The development of treatment-related adverse events (trAE) correlates favorably with clinical outcomes in multiple studies of patients receiving immune checkpoint inhibitors (ICI); however, this relationship is undefined in patients with hepa
Autor:
Nicola Personeni, ChiehJu Lee, Anushi Bulumulle, Anwaar Saeed, Abdul Rafeh Naqash, Petros Fessas, Tomi Jun, Musharraf Navaid, Bo Yu, Celina Ang, Yinghong Wang, Hannah Hildebrand, Ahmed Kaseb, David J. Pinato, Jingky Lozano-kuehne, Tiziana Pressiani, Dominik Bettinger, David Szafron, Thomas U. Marron, Lorenza Rimassa, Mahvish Muzaffar, Yehia I. Abugabal, Sirish Dharmapuri, Uqba Khan, Sonal Paul, Yi Hsiang Huang, Neil Nimkar
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
The impact of corticosteroid therapy (CT) on efficacy of immune checkpoint inhibitors (ICI) is undefined in hepatocellular carcinoma (HCC). We evaluated whether CT administered at baseline (bCT) or concurrently with ICI (cCT) influences overall (OS),
Autor:
Uqba Khan, Sonal Paul, Petros Fessas, Yehia I. Abugabal, Sirish Dharmapuri, Anushi Bulumulle, Celina Ang, Yi Hsiang Huang, Tomi Jun, Francesca Benevento, Bo Yu, David Szafron, Ahmed Kaseb, David J. Pinato, Tiziana Pressiani, Lorenza Rimassa, Yinghong Wang, Neil Nimkar, Anwaar Saeed, Chieh Ju Lee, Thomas U. Marron, Mahvish Muzaffar, Nicola Personeni, Hannah Hildebrand, Dominik Bettinger, Abdul Rafeh Naqash, Musharraf Navaid
Publikováno v:
Journal for Immunotherapy of Cancer
BackgroundNivolumab is Food and Drug Administration approved in sorafenib-experienced, advanced hepatocellular carcinoma (HCC). Post-registration data of treatment in a real-world setting is lacking.Patients and methodsWe performed an international,